Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OMALIZUMAB Cause Liver function test increased? 129 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 129 reports of Liver function test increased have been filed in association with OMALIZUMAB (Omalizumab-igec). This represents 0.2% of all adverse event reports for OMALIZUMAB.

129
Reports of Liver function test increased with OMALIZUMAB
0.2%
of all OMALIZUMAB reports
12
Deaths
112
Hospitalizations

How Dangerous Is Liver function test increased From OMALIZUMAB?

Of the 129 reports, 12 (9.3%) resulted in death, 112 (86.8%) required hospitalization, and 11 (8.5%) were considered life-threatening.

Is Liver function test increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OMALIZUMAB. However, 129 reports have been filed with the FAERS database.

What Other Side Effects Does OMALIZUMAB Cause?

No adverse event (9,736) Asthma (9,354) Urticaria (9,231) Off label use (9,199) Dyspnoea (8,323) Drug ineffective (6,747) Cough (5,926) Pruritus (5,224) Fatigue (5,053) Malaise (4,820)

What Other Drugs Cause Liver function test increased?

METHOTREXATE (3,839) ADALIMUMAB (2,070) ETANERCEPT (1,829) LEFLUNOMIDE (1,521) ABATACEPT (1,415) TOCILIZUMAB (1,406) RITUXIMAB (1,325) SULFASALAZINE (1,263) HYDROXYCHLOROQUINE (1,259) TOFACITINIB (1,221)

Which OMALIZUMAB Alternatives Have Lower Liver function test increased Risk?

OMALIZUMAB vs OMAVELOXOLONE OMALIZUMAB vs OMBITASVIR OMALIZUMAB vs OMBITASVIR\PARITAPREVIR\RITONAVIR OMALIZUMAB vs OMEGA-3-ACID ETHYL ESTERS OMALIZUMAB vs OMEGA-3-CARBOXYLIC ACIDS

Related Pages

OMALIZUMAB Full Profile All Liver function test increased Reports All Drugs Causing Liver function test increased OMALIZUMAB Demographics